

Virus Name: Salehabad		Abbreviation: SALV
Status Possible Arbovirus	Select Agent No	SALS Level 2
SALS Basis Results of SALS surveys and information from the Catalogue.		
Other Information		
Antigenic Group Phlebotomus Fever		

SECTION I - Full Virus Name and Prototype Number

Prototype Strain Number / Designation I-81	Accession Number	Original Date Submitted 7/9/1984
Family Bunyaviridae	Genus Phlebovirus	
Information From Robert B. Tesh	Address Yale Arbovirus Research Unit	
Information Footnote Revised		

Section II - Original Source

Isolated By (name) William Suyemoto (1)	Isolated at Institute Walter Reed Army Institute of Research	
Host Genus Phlebotomus spp. (pool of 105)	Species	Host Age/Stage Adult
Sex Female		
<u>Isolated From</u>	<u>Isolation Details</u>	
Signs and Symptoms of Illness	Arthropod	
Time Held Alive before Inoculation		
Collection Method Caught by hand	Collection Date 9/8/1959	
Place Collected (Minimum of City, State, Country) Salehabad, Iran		
Latitude 32° 0' N	Longitude 49° 0' E	
Macrohabitat Rural village	Microhabitat Houses	Method of Storage until Inoculated At -70dC
Footnotes		

Section III - Method of Isolation

Inoculation Date 1/15/1960	
Animal (Details will be in Section 6) nb mice	
Route Inoculated Intracerebral	Reisolation Yes
Other Reasons	
Homologous Antibody Formation by <u>Source Animal</u>	
Test(s) Used	
Footnotes	

Section IV - Virus Properties

Physicochemical RNA, Single Strand		
Pieces (number of genome segments) 3	Infectivity	Sedimentation Coefficients(s) (S)
Percentage wt, of Virion Protein	Lipid	Carbohydrate
Virion Polypeptides: Number	Details	
Non-virion Polypeptides: Number	Details	
Virion Density	Sedimentation Coefficients(s) (S)	
Nucleocapsid Density	Sedimentation Coefficients(s) (S)	
<hr/>		
<u>Stability of Infectivity (effects)</u>		
pH (infective range)		
Lipid Solvent (ether - % used to test)	After Treatment Titer	Control Titer
Lipid Solvent (chloroform) 20%	After Treatment Titer 1.5 dex	Control Titer 5.7 dex (1)
Lipid Solvent (deoxycholate) 1:1000	After Treatment Titer 3.2 dex	Control Titer 7.0 dex (1)
Other (formalin, radiation)		
<hr/>		
<u>Virion Morphology</u>		
Shape	Dimensions	
Mean nm	Range nm	
Measurement Method	Surface Projections/Envelope	Nucleocapsid Dimensions, Symmetry

Morphogenesis

Site of Constituent Formation in Cell	Site of Virion Assembly	Site of Virion Accumulation
Inclusion Bodies	Other	

Hemagglutination

Hemagglutination Yes	Antigen Source SMB ext. by sucrose-acetone + sonication (2)	Erythrocytes (species used) Various
pH Range 6.0-6.4	pH Optimum 6.0	
Temperature Range	Temperature Optimum Not dependent	

Remarks

Use of trypsin-treated erythrocytes enhances agglutination (2)

Serologic Methods Recommended

CF, NT, HI

Footnotes

Use of trypsin-treated erythrocytes enhances agglutination (2)

Section V - Antigenic Relationship and Lack of Relationship to Other Viruses

In cross-CF tests using SAL antigen and immune serum, no reactions were obtained with FRI, CAI, NIQ, AGU, CAC, BUE, PT, CHG, ICO, CDU, ITP, URU, PAC, ANH, BUJ, AMT, SFS, SFN, GF, KAR, or CHV antigens or immune sera [2].
Plaque neutralization tests [3]:

Virus	Antibody	
	Salehabad	Homologous
Salehabad	1280 *	1280
Arumowot	40	10240
Candiru	10	320
Frijoles	80	10240
Itaporanga	80	160

* Reciprocal of highest serum dilution producing >90% plaque reduction.

In cross-neutralization tests, SAL virus and immune serum were negative when tested against AGU, ALE, ANH, BUE, BUJ, CAC, CAI, CHG, CHI, GF, GOR, TEH, ICO, TOS, ITA, KAR, SFN, SFS, NIQ, PAC, PT, RVF, RG, TUA, and URU viruses and immune reagents [4], [5].

Virus Source (all VERTEBRATE isolates)

Lab Methods of Virus Recovery (ALL ISOLATIONS)
Newborn mice

Cell system (a)	Virus passage history (b)	Evidence of Infection						
		CPE			PLAQUES			Growth Without CPE +/- (g)
		Day (c)	Extent (d)	Titer TCD50/ml (e)	Day (c)	Size (f)	Titer PFU/ml (e)	
Vero (CL)	SM16 Vero 1				6-8	1 mm	6.2** (4)	
Hamster embryo (PC)	SM18	2	CPE produced		8	3-4 mm	8.0 (6)	
BHK-21 (CL)	SM16	4-5	3+	7.0** (7)				
LLC-MK2 (CL)	SM16				3	1 mm	7.5 (10)	

** Expressed in dex

Vertebrate (species and organ) and arthropod	No. isolations/No. tested	No. with antibody/No. tested Test used	Country and region
Phlebotomus spp. (females)	1/40 pools		Iran (1)
Phlebotomus spp. (females)	0/10,615		Iran (8)
Man		6/245 HI	Pakistan (1)
Man		6/93 HI	Bangladesh (1)
Cattle		0/68 HI	Pakistan (1)
Sheep		2/21 HI	
Rattus norvegicus		0/12 HI	
Pigeon		0/20 HI	
Quail (pools of 2 each)		0/16 HI	
Sparrow (pools of 3 each)		0/5 HI	

Plaque neutralization tests done on a large number of human sera from Iran and elsewhere in the Middle East as well as animal sera were all negative for Salehabad antibodies (5,9). Infection with this virus is apparently much less common than with SFS, SFN, or KAR viruses.

Section VIII - Susceptibility to Experimental Infection (include viremia)

Experimental host and age	Passage history and strain	Inoculation Route-Dose	Evidence of infection	AST (days)	Titer log ₁₀ /ml
Mice (nb)	SM 11, I-81	ic 0.02	Death	4.5	5.6 (1)
Mice (nb)		ip			
Mice (nb)		sc			
Mice (wn)	SM 22, I-81	ic 0.03	Death		6.7 (1)
Mice (wn)		ip			
hamsters (nb)	SM 16, I-81	ic	Death (4)		

Section IX - Experimental Arthropod Infection and Transmission

Arthropod species & virus source(a)	Method of Infection log ₁₀ /ml (b)		Incubation period (c)		Transmission by bite (d)		Assay of arthropod, log ₁₀ /ml (e)		
	Feeding	Injected	Days	°C	Host	Ratio	Whole	Organ	System

Section X - Histopathology

Character of lesions (specify host)

Inclusion Bodies

Intranuclear

Organs/Tissues Affected

Category of tropism

Section XI - Human Disease

In Nature	Residual	Death
Subclinical	Overt Disease	
Clinical Manifestations		
Number of Cases	Category (i.e. febrile illness, etc.)	

Section XII - Geographic Distribution

Known (Virus detected) Iran (1)
Suspected (Antibody only detected) Pakistan, Bangladesh

Section XIII - References

1. Berge, T.O., ed. International Catalogue of Arboviruses Including Certain Other Viruses of Vertebrates. Second Edition. DHEW Pub. No. (CDC) 75-8301. Atlanta, 1975. pp. 618-619.
2. Gaidamovich, S. Ya. and Kurakhmedova, Sh.A. 1974. Arch. ges. Virusforsch. 45:177-184.
3. Tesh, R.B., et al. 1975. Am. J. Trop. Med. Hyg. 24:135-144.
4. Tesh, R.B. Unpublished data.
5. Tesh, R.B., et al. 1976. Bull. WHO 54:663-674.
6. Salim, A.R. 1967. Am. J. Trop. Med. Hyg. 16:92-98.
7. Karabatsos, N. and Buckley, S.M. 1967. Am. J. Trop. Med. Hyg. 16:99-105.
8. Tesh, R., et al. 1966. Am. J. Trop. Med. Hyg. 26:282-287.
9. Saidi, S., et al. 1977. Am. J. Trop. Med. Hyg. 26:288-293.
10. Stim, T.B. 1969. J. Gen. Vriol. 5:329-338.
11. Tesh, R.B. 1975. J. Med. Ent. 12:1-4.

Remarks

--